Your browser doesn't support javascript.
loading
Detection of synthetic cannabinoid adulteration in the unregulated drug supply in three Canadian settings.
Ti, Lianping; Tobias, Samuel; Maghsoudi, Nazlee; Milloy, M-J; McDonald, Karen; Shapiro, Aaron; Beriault, Daniel; Stefan, Cristiana; Lysyshyn, Mark; Werb, Daniel.
Afiliação
  • Ti L; British Columbia Centre on Substance Use, Vancouver, Canada.
  • Tobias S; Department of Medicine, University of British Columbia, Vancouver, Canada.
  • Maghsoudi N; British Columbia Centre on Substance Use, Vancouver, Canada.
  • Milloy MJ; Centre on Drug Policy Evaluation, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada.
  • McDonald K; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada.
  • Shapiro A; British Columbia Centre on Substance Use, Vancouver, Canada.
  • Beriault D; Department of Medicine, University of British Columbia, Vancouver, Canada.
  • Stefan C; Centre on Drug Policy Evaluation, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada.
  • Lysyshyn M; British Columbia Provincial Toxicology Centre, Vancouver, Canada.
  • Werb D; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
Drug Alcohol Rev ; 40(4): 580-585, 2021 05.
Article em En | MEDLINE | ID: mdl-33354869
ABSTRACT

INTRODUCTION:

Novel psychoactive substances (NPS) are increasingly being consumed worldwide, with synthetic cannabinoids and synthetic opioids being the second and third most commonly used NPS, respectively. Certain synthetic cannabinoids can produce significant harms, particularly when used with opioids. The objective of this study was to characterise the presence of synthetic cannabinoids in the unregulated drug supply in three Canadian settings

METHODS:

In the British Columbia setting, all samples were first analysed at point-of-care using combination Fourier-transform infrared (FTIR) spectroscopy and fentanyl immunoassay strips prior to confirmatory testing using quantitative nuclear magnetic resonance spectroscopy, gas chromatography/mass spectrometry (GC/MS) and/or liquid chromatography/mass spectrometry (LC/MS). In the Toronto, Ontario setting, the samples were analysed directly by GC/MS, LC/MS liquid chromatography-high resolution/mass spectrometry.

RESULTS:

Between January 2018 and December 2019, 38 (2.8%) synthetic cannabinoid samples were detected in the unregulated drug supply (25/909 in British Columbia and 13/440 in Ontario). In British Columbia and Ontario, 76% and 85% of samples, respectively, were expected by individuals to be an opioid. Synthetic cannabinoids detected included AMB-FUBINACA, AB-FUBINACA, 5-fluoro-MDMB-PINACA, and 5-fluoro-MDMB-PICA, and largely co-occurred with fentanyl. In the British Columbia context, Fourier-transform infrared spectroscopy failed to detect synthetic cannabinoid compounds in almost half (48%) of the samples at point-of-care. DISCUSSION AND

CONCLUSIONS:

As point-of-care technologies failed to detect these compounds in many occasions, our findings demonstrate the importance of laboratory confirmatory analysis to identify NPS. Given the high risk of harm associated with the consumption of synthetic cannabinoids, further research should investigate the reasons for adulteration.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Canabinoides / Drogas Ilícitas Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Canabinoides / Drogas Ilícitas Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2021 Tipo de documento: Article